330 related articles for article (PubMed ID: 29578103)
41. Acute administration of bronchodilators on exercise tolerance in treated COPD patients.
Vagaggini B; Nieri D; Malagrinò L; Antonelli S; De Cusatis G; De Simone C; Costa F; Paggiaro PL
Pulm Pharmacol Ther; 2011 Feb; 24(1):49-54. PubMed ID: 20970517
[TBL] [Abstract][Full Text] [Related]
42. Physiological Characterization of Preserved Ratio Impaired Spirometry in the CanCOLD Study: Implications for Exertional Dyspnea and Exercise Intolerance.
Phillips DB; James MD; Vincent SG; Elbehairy AF; Neder JA; Kirby M; Ora J; Day AG; Tan WC; Bourbeau J; O'Donnell DE;
Am J Respir Crit Care Med; 2024 Jun; 209(11):1314-1327. PubMed ID: 38170674
[No Abstract] [Full Text] [Related]
43. Effects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD.
Ramlal SK; Visser FJ; Hop WC; Dekhuijzen PN; Heijdra YF
Pulm Pharmacol Ther; 2014 Aug; 28(2):158-64. PubMed ID: 24076367
[TBL] [Abstract][Full Text] [Related]
44. A comparison of the effects of salbutamol and ipratropium bromide on exercise endurance in patients with COPD.
Oga T; Nishimura K; Tsukino M; Sato S; Hajiro T; Mishima M
Chest; 2003 Jun; 123(6):1810-6. PubMed ID: 12796154
[TBL] [Abstract][Full Text] [Related]
45. [Effect of ipratropium bromide on lung dynamic hyperinflation in patients with chronic obstructive lung disease].
Jorquera J; Díaz O; Lisboa C
Rev Med Chil; 2003 Jun; 131(6):605-12. PubMed ID: 12942587
[TBL] [Abstract][Full Text] [Related]
46. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease.
O'Donnell DE
Proc Am Thorac Soc; 2006 Apr; 3(2):180-4. PubMed ID: 16565429
[TBL] [Abstract][Full Text] [Related]
47. Exercise Ventilatory Inefficiency Adds to Lung Function in Predicting Mortality in COPD.
Neder JA; Alharbi A; Berton DC; Alencar MC; Arbex FF; Hirai DM; Webb KA; O'Donnell DE
COPD; 2016 Aug; 13(4):416-24. PubMed ID: 27077955
[TBL] [Abstract][Full Text] [Related]
48. Bronchodilator response of advanced lung function parameters depending on COPD severity.
Jarenbäck L; Eriksson G; Peterson S; Ankerst J; Bjermer L; Tufvesson E
Int J Chron Obstruct Pulmon Dis; 2016; 11():2939-2950. PubMed ID: 27932874
[TBL] [Abstract][Full Text] [Related]
49. The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging.
De Backer J; Vos W; Vinchurkar S; Van Holsbeke C; Poli G; Claes R; Salgado R; De Backer W
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):88-99. PubMed ID: 25004168
[TBL] [Abstract][Full Text] [Related]
50. Bronchodilator Responses in Respiratory Impedance, Hyperinflation and Gas Trapping in COPD.
Milne S; Hammans C; Watson S; Farah CS; Thamrin C; King GG
COPD; 2018; 15(4):341-349. PubMed ID: 29799289
[TBL] [Abstract][Full Text] [Related]
51. Dyspnea, ventilatory pattern, and changes in dynamic hyperinflation related to the intensity of constant work rate exercise in COPD.
Puente-Maestu L; García de Pedro J; Martínez-Abad Y; Ruíz de Oña JM; Llorente D; Cubillo JM
Chest; 2005 Aug; 128(2):651-6. PubMed ID: 16100150
[TBL] [Abstract][Full Text] [Related]
52. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.
Beeh KM; Wagner F; Khindri S; Drollmann AF
COPD; 2011 Oct; 8(5):340-5. PubMed ID: 21793716
[TBL] [Abstract][Full Text] [Related]
53. Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD - A randomised, multicentre, crossover trial.
Watz H; Mailänder C; May C; Baier M; Kirsten AM
Pulm Pharmacol Ther; 2017 Feb; 42():13-20. PubMed ID: 27940287
[TBL] [Abstract][Full Text] [Related]
54. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).
Watz H; Mailänder C; Baier M; Kirsten A
BMC Pulm Med; 2016 Jun; 16(1):95. PubMed ID: 27301417
[TBL] [Abstract][Full Text] [Related]
55. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease.
Ofir D; Laveneziana P; Webb KA; Lam YM; O'Donnell DE
Am J Respir Crit Care Med; 2008 Mar; 177(6):622-9. PubMed ID: 18006885
[TBL] [Abstract][Full Text] [Related]
56. Effect of obesity on respiratory mechanics during rest and exercise in COPD.
Ora J; Laveneziana P; Wadell K; Preston M; Webb KA; O'Donnell DE
J Appl Physiol (1985); 2011 Jul; 111(1):10-9. PubMed ID: 21350021
[TBL] [Abstract][Full Text] [Related]
57. Inhibitory effect of procaterol on exercise dynamic lung hyperinflation during the 6-min walk test in stable patients with chronic obstructive pulmonary disease.
Satake M; Takahashi H; Sugawara K; Kawagoshi A; Tamaki A; Homma M; Morita R; Sato K; Sano M; Shioya T
Arzneimittelforschung; 2011; 61(1):8-13. PubMed ID: 21355441
[TBL] [Abstract][Full Text] [Related]
58. Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease.
Ong KC; Kor AC; Chong WF; Earnest A; Wang YT
Am J Respir Crit Care Med; 2004 May; 169(9):1028-33. PubMed ID: 14977622
[TBL] [Abstract][Full Text] [Related]
59. Bronchodilator effect on ventilatory, pulmonary gas exchange, and heart rate kinetics during high-intensity exercise in COPD.
Laveneziana P; Palange P; Ora J; Martolini D; O'Donnell DE
Eur J Appl Physiol; 2009 Dec; 107(6):633-43. PubMed ID: 19711095
[TBL] [Abstract][Full Text] [Related]
60. Effect of heliox on lung dynamic hyperinflation, dyspnea, and exercise endurance capacity in COPD patients.
Palange P; Valli G; Onorati P; Antonucci R; Paoletti P; Rosato A; Manfredi F; Serra P
J Appl Physiol (1985); 2004 Nov; 97(5):1637-42. PubMed ID: 15234959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
